- HIV-negative plasmablastic lymphoma: report of 8 cases and a comprehensive review of 394 published cases
-
Li YJ, Li JW, Chen KL, Li J, Zhong MZ, Liu XL, Yi PY, Zhou H
- KMID: 2472008
- Blood Res.
- 2020 Mar;55(1):49-56.
- doi: 10.5045/br.2020.55.1.49
BACKGROUND: Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma (PBL) is a rare entity of diffuse large B-cell lymphoma (DLBCL). The clinicopathological features of and optimal treatment for HIV-negative PBL remain largely... -
- CITED
-
- Close
- SHARE
-
- Close
- Necrobiotic Xanthogranuloma Coexists with Diffuse Normolipidemic Plane Xanthoma and Multiple Myeloma
-
Kim JG, Kim HR, You MH, Shin DH, Choi JS, Bae YK
- KMID: 2467201
- Ann Dermatol.
- 2020 Feb;32(1):53-56.
- doi: 10.5021/ad.2020.32.1.53
Necrobiotic xanthogranuloma (NXG), is a rare multisystem disease that manifests as cutaneous inflammatory lesions, and is commonly associated with lymphoproliferative disease. Diffuse normolipemic plane xanthoma (NX), is also a rare,... -
- CITED
-
- Close
- SHARE
-
- Close
- Successful treatment of early acute antibody-mediated rejection in an human leukocyte antigen-incompatible and ABO-incompatible living-donor kidney transplant patient
-
Gang S, Han A, Min SI, Ha J, Yang J
- KMID: 2468166
- Korean J Transplant.
- 2019 Dec;33(4):153-158.
- doi: 10.4285/jkstn.2019.33.4.153
For successful human leukocyte antigen-incompatible (HLAi) or ABO-incompatible (ABOi) living-donor kidney transplantations (LDKTs), pretransplant desensitization is essential; however, early antibody-mediated rejection (ABMR) remains the most important complication after HLAi or... -
- CITED
-
- Close
- SHARE
-
- Close
- Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
-
Lee SR, Choi H, Lee BH, Kang KW, Yu ES, Kim DS, Park Y, Choi CW, Kim BS, Sung HJ
- KMID: 2463492
- Korean J Intern Med.
- 2019 Nov;34(6):1333-1346.
- doi: 10.3904/kjim.2018.144
BACKGROUND/AIMS: Bortezomib plus melphalan-prednisone (VMP) is a standard treatment for multiple myeloma, particularly for patients who are ineligible for high-dose therapy. However, early discontinuation or treatment modification is often needed... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Lenalidomide-induced Drug Eruption Presenting as Pruritus and Erythema Covering the Whole Body
-
Shin JY, Hong KR, Kim JE, Lee SH, Park YL
- KMID: 2446922
- Korean J Dermatol.
- 2019 Mar;57(3):149-151.
Lenalidomide is an immunomodulatory drug used for the treatment of multiple myeloma. Several cases of hematological, gastrointestinal, and cutaneous side effects have been reported for this drug. A 67-year-old patient... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Amyloidosis Presenting as Lymphadenopathy at the Porta Hepatis
-
Lee JI, Kim JS, Kim BW
- KMID: 2439832
- Korean J Helicobacter Up Gastrointest Res.
- 2018 Sep;18(3):209-212.
- doi: 10.7704/kjhugr.2018.18.3.209
We report a rare case of systemic amyloidosis with gastrointestinal and lymph node involvement. A 64-year-old woman was admitted to our hospital with dyspepsia and weight loss. Initial esophagogastroduodenoscopy (EGD)... -
- CITED
-
- Close
- SHARE
-
- Close
- Bortezomib Treatment for Refractory Antibody-Mediated Rejection Superimposed with BK Virus-Associated Nephropathy during the Progression of Recurrent C3 Glomerulonephritis
-
Do W, Lee JH, Kim KJ, Han MH, Jung HY, Choi JY, Park SH, Kim YL, Kim CD, Cho JH, Yang Y, Kim M, Hwang I, Kim KY, Yim T, Kim YJ
- KMID: 2421281
- J Korean Soc Transplant.
- 2018 Sep;32(3):57-62.
- doi: 10.4285/jkstn.2018.32.3.57
A 38-year-old man, who underwent a second kidney transplantation (KT), was admitted because of antibody-mediated rejection (AMR) complicated by BK virus-associated nephropathy (BKVAN). He was placed on hemodialysis at the... -
- CITED
-
- Close
- SHARE
-
- Close
- The Effect of Bortezomib on the Management of Immediate Postoperative Refractory Antibody-Mediated Rejection after Kidney Transplantation
-
Kim SJ, Jun KW, Hwang JK, Chung BH, Yang CW, Moon IS, Kim JI, Kim MH
- KMID: 2421280
- J Korean Soc Transplant.
- 2018 Sep;32(3):49-56.
- doi: 10.4285/jkstn.2018.32.3.49
BACKGROUND: Bortezomib has been used to treat antibody-mediated rejection (AMR) that usually develops after kidney transplantation (KT). Although it has been used in various clinical situations, it is difficult to... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical characteristics and outcomes of thrombotic microangiopathy in Malaysia
-
Yap YY, Sathar J, Law KB, Zulkurnain PAB, Edmund SC, Chang KM, Baker R
- KMID: 2451031
- Blood Res.
- 2018 Jun;53(2):130-137.
- doi: 10.5045/br.2018.53.2.130
BACKGROUND: Thrombotic microangiopathy (TMA) with non-deficient ADAMTS-13 (a disintegrin-like and metalloprotease with thrombospondin type 1 motif 13) outcome is unknown hence the survival analysis correlating with ADAMTS-13 activity is conducted... -
- CITED
-
- Close
- SHARE
-
- Close
- Inhibition of the 26S and 20S Proteasomes by the Site-specific Inhibitors
-
Woo KM
- KMID: 2437766
- Soonchunhyang Med Sci.
- 2018 Jun;24(1):47-54.
- doi: 10.0000/sms.2018.24.1.47
OBJECTIVE: The study was performed to establish the purification processes of both 26S and 20S proteasomes, also to investigate the inhibitory properties and patterns of two different proteasome inhibitors on... -
- CITED
-
- Close
- SHARE
-
- Close
- Chemotherapy adherence is a favorable prognostic factor for elderly patients with multiple myeloma who are treated with a frontline bortezomib-containing regimen
-
Cho HJ, Seo SK, Baek DW, Park SW, Lee YJ, Sohn SK, Lee HS, Lee WS, Lee JH, Kim SH, Moon JH
- KMID: 2415737
- Yeungnam Univ J Med.
- 2018 Jun;35(1):76-83.
- doi: 10.12701/yujm.2018.35.1.76
BACKGROUND: Elderly patients with multiple myeloma (MM) are vulnerable to adverse events (AEs). This study evaluated adherence to chemotherapy and treatment outcomes in elderly patients treated with a frontline bortezomib... -
- CITED
-
- Close
- SHARE
-
- Close
- Nutlin-3 enhances the bortezomib sensitivity of p53-defective cancer cells by inducing paraptosis
-
Lee DM, Kim IY, Seo MJ, Kwon MR, Choi KS
- KMID: 2389293
- Exp Mol Med.
- 2017 Aug;49(8):e365.
- doi: 10.1038/emm.2017.112
The proteasome inhibitor, bortezomib, is ineffective against many solid tumors. Nutlin-3 is a potent antagonist of human homolog of murine double minute 2/p53 interaction exhibiting promising therapeutic anti-cancer activity. In... -
- CITED
-
- Close
- SHARE
-
- Close
- Bortezomib-induced Histiocytoid Sweet Syndrome
-
Oh YJ, Lew BL, Sim WY
- KMID: 2359680
- Korean J Dermatol.
- 2016 Nov;54(9):739-743.
Sweet syndrome is an acute febrile neutrophilic dermatosis predominantly characterized by fever, an elevated neutrophil count, and erythematous skin lesions comprising plaques and nodules that mainly appear on the upper... -
- CITED
-
- Close
- SHARE
-
- Close
- Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party
-
Kim SJ, Bang SM, Choi YS, Jo DY, Kim JS, Lee H, Eom HS, Yoon DH, Suh C, Lee JJ, Hong J, Lee JH, Koh Y, Kim K, Yoon SS, Min CK, Korean Multiple Myeloma Working Party
- KMID: 2353501
- Blood Res.
- 2016 Sep;51(3):193-199.
- doi: 10.5045/br.2016.51.3.193
BACKGROUND: Bendamustine may be a potential treatment option for patients with myeloma, but little is known about the utility of bendamustine as a salvage treatment, especially in Asian patients. METHODS: We... -
- CITED
-
- Close
- SHARE
-
- Close
- Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients
-
Lee SS, Jung SH, Ahn JS, Kim YK, Cho MS, Jung SY, Lee JJ, Kim HJ, Yang DH
- KMID: 2373738
- J Korean Med Sci.
- 2016 Jul;31(7):1160-1163.
- doi: 10.3346/jkms.2016.31.7.1160
Peripheral T cell lymphoma (PTCL) is a heterogeneous group of aggressive lymphomas with poor prognosis. Elderly (age ≥ 65years) patients generally have impaired bone marrow function, altered drug metabolism, comorbidities,... -
- CITED
-
- Close
- SHARE
-
- Close
- Pretreatment Lymphopenia, Poor Performance Status, and Early Courses of Therapy Are Risk Factors for Severe Bacterial Infection in Patients with Multiple Myeloma during Treatment with Bortezomib-based Regimens
-
Hyun SY, Han SH, Kim SJ, Jang JE, Kim Y, Cho H, Lee JY, Cheong JW, Min YH, Song JW, Kim JS
- KMID: 2363688
- J Korean Med Sci.
- 2016 Apr;31(4):510-518.
- doi: 10.3346/jkms.2016.31.4.510
The aim of this study was to identify the risk factors associated with severe bacterial infection (SBI) in multiple myeloma (MM) patients during treatment with bortezomib-based regimens. A total of... -
- CITED
-
- Close
- SHARE
-
- Close
- Progression of Extramedullary Plasmacytoma in a Multiple Myeloma Patient with No Increment in Serum M Protein Level
-
Kim SH, Jee YG, Yeo WH, Sohn BS, Kim SR, Kim HJ, Yuh YJ
- KMID: 2268892
- Korean J Med.
- 2016 Jan;90(1):55-58.
- doi: 10.3904/kjm.2016.90.1.55
A 76 year-old female who was diagnosed with multiple myeloma (IgG, lambda) had received bortezomib, melphalan and prednisolone as first-line treatment. After completing six cycles of chemotherapy, her serum monoclonal... -
- CITED
-
- Close
- SHARE
-
- Close
- Two Cases of Bortezomib-induced Drug Eruption Presenting as Multiple Plaques on the Trunk
-
Choe YS, Kim EJ, Na JI
- KMID: 2245828
- Korean J Dermatol.
- 2016 Jan;54(1):47-51.
Bortezomib (Velcade(R)) is proteasome inhibitor that is used as a first-line therapy for multiple myeloma. It can cause gastrointestinal, hematologic, and neuromuscular side effects, and a cutaneous reaction is one... -
- CITED
-
- Close
- SHARE
-
- Close
- The Effect of Bortezomib on Antibody-Mediated Rejection after Kidney Transplantation
-
Lee J, Kim BS, Park Y, Lee JG, Lim BJ, Jeong HJ, Kim YS, Huh KH
- KMID: 2345894
- Yonsei Med J.
- 2015 Nov;56(6):1638-1642.
- doi: 10.3349/ymj.2015.56.6.1638
PURPOSE: Recently, bortezomib has been used to treat antibody-mediated rejection (AMR) refractory to conventional treatment such as plasmapheresis, intravenous immunoglobulin, and rituximab. The authors aimed to describe their experiences when... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Acute Pancreatitis Caused by Bortezomib in a Patient with Multiple Myeloma
-
Lim JH, Hwang KB, Lim BH, Jeong YH, Sohn KC, Kim TH
- KMID: 2448488
- Korean J Pancreas Biliary Tract.
- 2015 Jul;20(3):136-139.
- doi: 10.15279/kpba.2015.20.3.136
Bortezomib is a proteasome inhibitor used for the treatment of patients with multiple myeloma. Recently, several case reports about acute pancreatitis caused by Bortezomib were published in the international literature.... -
- CITED
-
- Close
- SHARE
-
- Close
